The obesity-related adipokine, leptin, has multiple actions on peripheral organs, including the mitigation of adverse cardiovascular outcomes after myocardial infarction (MI). Although we recently demonstrated that leptin, its receptor, and downstream signalling are up-regulated in the heart after MI, the significance of intact cardiomyoctye leptin signalling is unknown. Therefore, our objective was to generate a cardiomyocyte-specific leptin receptor knock-out (ObRKO) mouse to determine whether worse cardiac outcomes after MI result from impaired leptin signalling in cardiomyocytes.
Introduction
Adipose tissue produces and secretes a number of substances that act centrally to regulate appetite, metabolism, and cellular physiology. 1 Many of these 'adipokines' also mediate effects directly in peripheral tissues through membrane bound receptors. Within the heart, the adipokine leptin and its receptor (ObR) are abundantly expressed in cardiomyocytes. 2, 3 Leptin can regulate the baseline physiology of the heart, including myocyte contractility, 4 hypertrophy, 5 apoptosis, 6 and metabolism. 7, 8 During pathological states of myocardial infarction (MI) 9 and heart failure, 10 circulating leptin is increased, most likely from fat-derived sources. However, we have recently shown that increased expression of leptin and its receptor can occur locally in the failing human heart. 3 Moreover, we demonstrated in an experimental murine model of MI that whole-body leptin deficiency results in impaired cardiac structure, function, and survival 2, 11 and that the phenotype can be rescued by the systemic repletion of leptin. However, the question remains as to whether the beneficial effects of leptin repletion in the setting of MI are dependent on leptin signalling in cardiomyocytes or secondary to the multiple effects of leptin peripheral to the heart. Thus, the first goal of our study was to determine whether or not the cardiac-specific disruption of ObR expression, through the development of a mouse with inducible excision of the ObR gene, impacted on cardiac outcomes after MI. We hypothesized that a loss of cardiomyocyte-specific ObR expression would lead to greater decrements in cardiac structure and function, as well as increased myocardial apoptosis, inflammation, and hypertrophy, post-MI. The second goal of our study was to establish whether or not the disruption of cardiac ObR expression also impairs activation of downstream signalling pathways that are known to provide cardioprotective benefit in MI, including signal transducer and activator of transcription (STAT) 3 and adenosine monophosphate-activated protein kinase (AMPK). In particular, since it is known that AMPK is a key regulator of cardiac substrate metabolism, 12 we further hypothesized that the ability of the ischaemic, failing heart to anaerobically metabolize glucose is dependent on an intact ObR-AMPK signalling axis.
Methods

Animals
All animal use conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Previously characterized mice harbouring the floxed ObR gene 13 were a gift of Dr Jeff Friedman (Rockefeller University, NY, USA) and were bred into a pure C57BL/6J background for 8+ generations prior to subsequent breeding with mice homozygous for the a-myosin heavy chain promoter driven MerCreMer transgene (Jackson Laboratories, USA, B6129SF1/J background, stock #005650 ObRKO administered the leptin-independent AMPK activator, aminoimidazole carboxamide ribonucleotide (AICAR), at a dose of 0.5 mg/g ip daily starting at 3 days prior to animal sacrifice (n ¼ 9). In a separate set of experiments, an additional five (for sham groups) or eight (for CAL groups) mice were examined per group for cardiac glycolytic metabolism. Finally, an additional set of ObRKO mice were treated with oil (n ¼ 10) or tam (n ¼ 10), subjected to CAL, and administered leptin (n ¼ 5 per tam/oil group at a dose of 0.3 mg/kg ip) or equal volume saline (n ¼ 5 per tam/ oil group) after 1 month, followed by animal sacrifice 30 min later.
Genotyping
DNA extraction from tissue was accomplished using the Extract-N-Amp kit (Sigma Aldrich, USA) per manufacturer's instructions. Primers and PCR conditions used are detailed in the Supplementary material online. PCR products were visualized using agarose gel electrophoresis.
Echocardiography
Parasternal short-axis B-and m-mode images were obtained on mice under 1 -2% isoflurane anaesthesia using a Visualsonics echocardiography machine as previously described 2 and detailed in the Supplementary material online. 
In vivo pressure-volume loops
Quantitative real-time RT-PCR analysis
Total RNA was isolated from whole heart homogenates and subjected to quantitative PCR, as previously described, 2 and detailed in the Supplementary material online.
Western blotting/zymography
Protein was extracted from whole heart homogenates in RIPA buffer and subjected to SDS -PAGE in equal amounts as described previously. 2 Antibodies and incubation conditions used are detailed in the Supplementary material online.
Immunofluorescence/histology
Mouse cardiac sections were used for ObR, TUNEL, CD45, a-actinin, picrosirius-red, phalloidin, and H&E stains as previously described 2 and detailed in the Supplementary material online. The determination of apoptotic and inflammatory indices, as well as collagen fractional area, was accomplished using the image analysis software Metamorph v7.5 (Molecular Devices, USA).
Determination of infarct size, cardiomyocyte area, and width
Mouse cardiac sections were stained with FITC-linked wheat germ agglutinin (to visualize cell membranes) and DAPI (to visualize nuclei) or H&E, and the determination of infarct area and cardiomyocyte dimensions was accomplished using Image J software (NIH), all as previously described, 2 and detailed in the Supplementary material online.
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In vitro caspase-3 activity assay
Caspase-3 activity was determined using whole heart homogenates and the caspase-3/CPP32 Colorimetric Assay kit (Biovision, USA) as previously described 11 and detailed in the Supplementary material online.
Statistics
Data presented are mean + standard error of the mean (SEM). Statistical significance of mean changes was determined by ANOVA with post hoc comparisons between means using Bonferrroni's simultaneous tests. Mathematical calculations, determination of P values, Student's t-tests, ANOVAs, and the Kaplan-Meier log-rank survival statistics and survival graph were generated using the computer program Statistical Package for the Social Sciences (SPSS) v17 (SPSS, USA). Figure 1A ). This was accompanied by a reduction in cardiac ObR mRNA and protein expression to 14 + 3 and 13 + 1% of oil-treated control levels, respectively ( Figure 1B) . Immunofluorescent examination of cardiac sections showed a marked reduction in ObR expression in cardiomyocytes (see Supplementary material online, Figure S1A ). All mice maintained a lean phenotype and demonstrated no confounding tam effects 16 on cardiac structure and function after tam treatment, with mean end-diastolic dimensions (EDDs), enddiastolic volumes (EDVs), average wall thicknesses, left ventricular ejection fractions, fractional shortenings (FSs), and developed pressures unchanged in sham mice after 7 days of tam treatment relative to oil treatment ( Tables 1 and 2 ; see Supplementary material online, Figure S1B ).
Cardiac-specific reduction in ObR expression results in a loss of cardiac STAT3 and AMPK signalling at 1-month post-MI
We have previously established that cardiac ObR expression and STAT3 signalling are increased in wild-type mice at 1-month post-MI. 2 Here, we again utilized STAT3 phosphorylation as a read-out of leptin signalling 17 online, Figure S2B ) only in oil-treated ObRKO mice. In control experiments, both total and p/t-STAT3 and -AMPK in tam-treated parental MerCreMer +/+ and ObR floxed +/+ mice were not significantly different from oil-treated ObRKO mice post-MI (Figure 2A and B) . Supplementary material online, Figure S3 ), both heart and lung weights of tam-treated ObRKO mice were significantly increased, and tamtreated ObRKO mice subjected to CAL demonstrated the greatest increase in EDD and end-systolic dimension, and the greatest decrease in per cent FS, at 3-day, 1-, 2-, and 3-week, and 1-month post-surgery (see Supplementary material online, Figure S4 and Table  S1 ; Table 1 and Figure 3A) . These exacerbated indices of heart failure in the tam-treated ObRKO mouse post-MI were consistent with pressure -volume data at 1-month post-MI, which demonstrated significant increases in EDV and end-systolic volume, and significant decreases in cardiac output, ejection fraction, and developed pressures ( Table 2 and Figure 3B ). 2 and Figure 3A and B). Consistent with the literature, 18, 19 AICAR administration resulted in the activation of cardiac AMPK ( Figure 3C) , and significant improvements in both echocardiographic-and pressure-volume-determined indices of heart failure were observed ( Figure 3D , and Tables 1 and 2 ). Table S2 ). Further, both myocyte width and area ( Figure 4B ; see Supplementary material online, Figure S5 ), as well as echocardiographic determination of wall thicknesses ( Figure 3A and Table 1 ), were increased post-MI in tam relative to oil-treated ObRKO mice, or tam-treated homozygous (+/+) MerCreMer (Cre +/+ ) and floxed (flox +/+ ) parental mice.
Moreover, increased deposition of collagen was observed in cardiac sections from tam-treated ObRKO mice ( Figure 4C ; see Supplementary material online, Figure S6 ) and correlated with increased zymographically determined matrix metalloproteinase (MMP) 2 and 9 activity ( Figure 4D ). With AICAR administration, tam-treated ObRKO mice demonstrated significant reductions in foetal gene and inflammatory cytokine mRNA expression, myocyte hypertrophy, collagen deposition, and MMP activity ( Figure 4A -D, Table 1 ; see Supplementary material online, Figures S5 and S6) . floxed (flox +/+ ) parental mice, relative to shams ( Figure 6 ). In tamtreated ObRKO mice, glycolytic rate was significantly impaired in both sham and infarcted hearts, and complete rescue was seen in CAL mice after AICAR administration ( Figure 6 ).
Discussion
Here, we establish that leptin has a direct effect on the heart by demonstrating that cardiomyocyte-restricted loss of leptin signalling results in worse cardiac structure, function, and survival relative to wild-type mice after experimental MI, consistent with our previous observations in the whole-body leptin-deficient Ob/Ob mouse.
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We go on to demonstrate that intact cardiac leptin signalling in ischaemic heart failure is important for the maintenance of glycolytic metabolism, involves the activation of STAT3 and AMPK, and is associated with attenuated indices of inflammation, apoptosis, and adverse cardiac remodelling post-MI. By demonstrating improvement in many exacerbated indices of cardiac structure and function that occur in the tam-treated ObRKO mouse post-MI with AICAR, we mechanistically link the cardioprotective benefit of leptin signalling to AMPK. Taken together, these results provide potential mechanisms by which intact leptin signalling improves outcomes in ischaemic heart failure.
In the present study, experiments using the ObRKO mouse demonstrate the relative importance of cardiac vs. non-cardiac leptin signalling in the ischaemic failing heart and suggest a compensatory role for the increased ObR expression that occurs in wild-type mice post-MI 2, 20 and in humans with heart failure. 3 Specifically, in
ObRKO mice with reduced cardiac ObR expression, a corresponding loss of STAT3 and AMPK activation is seen in the failing heart. The importance of this finding is that STAT3 and AMPK activation mitigates cardiac ischaemic injury. For example, in mice with a loss of STAT3 activation, greater adverse left ventricular remodelling 21 and increased apoptosis 22 occur post-MI. Similarly, in mice expressing the kinase inactive form of AMPK, ischaemic glucose uptake and glycolysis are impaired, and post-ischaemic cardiac function and apoptosis are exacerbated. 23 Our results using the ObRKO mouse are consistent with these 21 -23 published reports and demonstrate that a loss of cardiac STAT3 and AMPK activation in the ischaemic failing heart is linked to increased levels of adverse structural, functional, biochemical, and metabolic remodelling. Our data demonstrate that excision of the ObR gene has no effect on the basal activation state of STAT3 or AMPK, or on myocardial structure or contractile performance during a short (4 week) period of observation. Indeed, data from Ob/Ob and Db/Db mice suggest that longer perturbation of ObR signalling is required to see changes in cardiac structure and function under basal conditions 5 and that ischaemic injury 2, 24 accelerates this process. Combined, these in vivo data 2, 5, 24 are in contrast to several, 25 -27 but not all, 28 in vitro studies reporting that leptin can induce hypertrophy in cultured rat neonatal or human paediatric cardiomyocytes. Reasons for these varied in vivo vs. in vitro responses may be due to a number of factors, including the reported lack of long-form ObR expression in rat neonatal cardiomyocytes, 26 the lack of non-cardiomyocyte cells in culture preparations that secrete factors such as angiotensin-(1-7) 29 and interferon-g 30 that mediate anti-hypertrophic effects, the loss of extracellular matrix (ECM) that provides and/or alleviates varied degrees of wall stress in vivo, 31 and the different culture conditions under which experiments were performed. The acute effect of leptin administration may also be different than the chronic effect of deficiency. In particular, it has been proposed that the age-related hypertrophy observed in Ob/Ob and Db/Db mice is a consequence of many deranged physiological parameters that occur in these mice over time and is not a direct consequence of leptin deficiency per se. 25 Although our data do not directly address the issue of age-related hypertrophy in states of leptin deficiency, we do demonstrate using our cardiac-specific ObR knockout mouse that the mitigating effects of leptin on post-MI hypertrophy are specific to cardiac tissue and not dependent on any systemic actions of leptin. Thus, although final conclusions regarding leptin-mediated cardiomyocyte hypertrophy based on in vitro data remain to be clarified, our data suggest that impaired cardiac leptin signalling post-MI results in a decrease in AMPK activity and an increase in cardiomyocyte hypertrophy. Cardiomyocyte hypertrophy can develop as a compensatory response to increases in cardiac pressure and/or volume. However, with time, hypertrophy leads to cardiac failure, characterized by maladaptive remodelling of the ECM, reduced contractile performance, and ventricular dilation. Inflammation plays a role in regulating ECM remodelling by contributing to alterations in cardiac MMP activity and collagen deposition. 31 Specifically, mast cells within the myocardium release a variety of factors, including TNFa, that increase MMP expression and activation, 32 and evidence suggests that both neutrophils and macrophages secrete and activate MMPs in the post-MI heart. 33 Consistent with these observations, we show increased cardiac MMP activity, collagen deposition, inflammatory cytokine expression (including TNFa), and increased inflammatory cell infiltrates in tam-treated ObRKO mice post-MI. Further, we demonstrate a reduction in these measures with AICAR administration, suggesting the involvement of AMPK. This is consistent with other reports 34, 35 demonstrating that AMPK modulates inflammatory responses. In particular, AMPK not only suppresses pro-inflammatory responses in macrophages, 34 but it also inhibits the production and activity of pro-inflammatory cytokines such as TNFa. 35 Thus, impaired cardiac leptin signalling post-MI is linked to decreased AMPK TNFa-, 37 and ischaemia/reperfusion 23 -induced cardiac apoptosis. We speculate that complete normalization of apoptotic rates was not achieved in our study, however, due to either the relatively short duration of AICAR administration, and/or the involvement of additional leptin-dependent, but AMPK-independent, antiapoptotic factors and pathways. For example, in addition to AMPK, 36 evidence suggests that leptin attenuates apoptosis in cardiac cells through the activation of p38 mitogen-activated kinase, 36 phosphoinositide 3-kinase, 38 and STAT3. 11 Nevertheless, our experiments using AICAR confirm a mechanistic link and demonstrate a unique AMPKdependent anti-apoptotic role for leptin in the ischaemic failing heart. Our data demonstrate that leptin impacts hypertrophy, collagen deposition, MMP activity, inflammation, and apoptosis in the ischaemic failing heart and thereby plays an important role in mitigating adverse structural remodelling post-MI. Another major finding in this study is that leptin also mediates metabolic remodelling in ischaemic heart failure. Specifically, we demonstrate increased glycolysis post-MI only in hearts with intact leptin signalling and reduced glycolytic rates in mice with impaired leptin signalling that can be rescued with AICAR. These results are in agreement with findings in Ob/Ob and Db/Db mice that show a reduction in cardiac glucose utilization and contractile function that precede the development of obesity and hyperglycaemia. 7, 39 Given these observations, it is likely that the reduction in anaerobic metabolism we see in hearts with impaired leptin signalling is a major contributing factor to the accentuated impairments we see in LV systolic function, cardiac output, stroke work, and contractility (dP/dt max ) in the tam-treated ObRKO mouse post-MI. Indeed, independent of leptin, studies consistently demonstrate a significant reduction in cardiac mechanical efficiency when free fatty acids are used preferentially over glucose for energy production in the failing heart. 40 Our data demonstrating restoration of glycolysis and significant improvements in cardiac function with AICAR treatment suggest a direct link between leptin-mediated glycolytic metabolism and cardiac function post-MI, and highlight the dependence on AMPK in the process.
In conclusion, our data show that leptin mitigates heart failure post-MI by acting directly on the cardiomyocyte to increase ObR signalling and decrease cardiac hypertrophy, apoptosis, and inflammation. Further, our results demonstrate that intact cardiac leptin signalling is an important mediator of anaerobic metabolism which occurs in the ischaemic failing heart and is associated with less severe decrements in cardiac function and apoptosis post-MI.
Together, these observations complement studies reporting increased circulating leptin acutely after MI 9 and increased cardiac ObR expression 3 and circulating leptin 10 in human heart failure, by establishing a cardiomyocyte-specific role for leptin to improve outcomes in cardiac ischaemic injury.
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